THE IMPACT OF RARE DISEASES ON HEALTH RELATED QUALITY OF LIFE

Amar Abbas, Janis Vella Szijj, Anthony Serracino Inglott
Department of Pharmacy, Faculty of Medicine and Surgery, University of Malta, Msida, Malta
e-mail: anthony.serracino-inglott@u.edu.mt

INTRODUCTION

Over 7000 Rare Diseases (RDs) affect around 60 million patients living in the European Union (EU) and the United States (US). More than 80% of RDs are genetic and appear early in life, resulting in a 30% mortality rate in children diagnosed before their fifth birthday.

RDs are chronic and result in a decreased Quality of Life (QOL).

AIMS

To develop a QOL assessment tool for RD patients to identify issues of accessibility, diagnosis, information provision at the time of diagnosis, personal care and independence and mental health.

METHOD

A self-administered Health Related QOL assessment tool was developed. The assessment tool consisted of 30 questions which were divided into 4 main sections: ‘Demographics’, ‘Personal Care and Independence’, ‘Mental and Social Health’ and ‘Accessibility to Orphan Drugs.’

The tool was validated by seven experts: 3 pharmacists, 2 researchers, 1 clinician and 1 RD patient.

RESULTS

Two hundred and twenty five responses were gathered. Eighty-two of the respondents were male. One hundred and thirty five patients stated that they received a misdiagnosis in relation to their condition. Fifty four patients stated that it took 5 years or more for them to receive a correct diagnosis of their condition.

Forty four patients claimed that it was difficult for them to be able to afford orphan drugs prescribed to them and 71 patients claimed that it was almost impossible for them to afford their medication. Twenty nine patients claimed that no medications were available for their condition.

US patients face larger financial burdens and have greater accessibility issues than EU RD patients (p<0.05). There was a significant QOL difference between EU and US RD patients (p<0.05) as the Europeans reported having a better QOL in relation to personal care and independence (Table 1) and mental and social health.

CONCLUSION

RD patients face challenges related to diagnoses of their condition and QOL. Accessibility of Orphan Drugs depended on pricing, re-imbursement policies and product availability. There is a need for improvement in the QOL of RD patients given the high cost of illness, mental health problems and poor accessibility.

REFERENCE